ZNTL Stock Price - Zentalis Pharmaceuticals, Inc. logo

ZNTL Stock Price

Zentalis Pharmaceuticals, Inc.

$1.36
-$0.13(-8.72%)
37
Overall
60
Value
27
Tech
26
Quality
How is this score calculated?
Market Cap
$133.64M
Volume
1.21M
52W Range
$1.28 - $6.95
Target Price
$7.80

ZNTL stock price is $1.36 (-8.72% on the day), giving Zentalis Pharmaceuticals, Inc. a market cap of $133.64M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.

ZNTL Stock Overview

Price
$1.36
Previous close
$1.49
Open
$1.50
Market cap
$133.64M
52-week range
$1.28 - $6.95
1-year price target
$7.80
Sector
Healthcare
Industry
Biotechnology
Exchange
Nasdaq
MarketXLS Rank
37

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.

ABCD
1SymbolPriceChangeVol
2ZNTL$1.36-8.7%1.21M
3
4
5
6

Get Zentalis Pharmaceuticals, Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.